JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
102 hedge funds and large institutions have $120M invested in Jounce Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 35 increasing their positions, 32 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
102
Holders Change
-11
Holders Change %
-9.73%
% of All Funds
1.72%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
15
Increased
35
Reduced
32
Closed
23
Calls
$82K
Puts
–
Net Calls
+$82K
Net Calls Change
+$102K
Top Buyers
| 1 |
CAC
Cowen and Company
New York
|
$8.62M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
$3.84M |
| 3 |
BlackRock
New York
|
$8.07M |
| 4 |
Renaissance Technologies
New York
|
$640K |
| 5 |
Invesco
Atlanta,
Georgia
|
$576K |
